Introduction

Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disease, characterized by progressive pareses.\(^1,2\) Despite the emphasis on the motor neurons, ALS has evolved to be regarded as a multisystem disorder,\(^3\) given that it affects several brain regions in a distinctive propagation pattern.\(^4\) In the clinical diagnostic processes, neuroimaging with magnetic resonance imaging (MRI) has an essential role in the exclusion of other etiologies of the clinical presentation.\(^5\) In addition, MRI approaches with advanced postprocessing, focused on but not limited to diffusion-weighted imaging techniques, have been established as biological markers of the disease with reliable measures for monitoring...
disease progression and have greatly improved our understanding of its in vivo pathoanatomy.6,7 In the search for features of diagnostic classifiers, the integration of multiparametric MRI including diffusion tensor imaging (DTI), volumetric, and texture data may be the best approach to generate a neuroimaging-based diagnostic tool for ALS, also for multicenter studies.9,10 In that context, the role of dedicated advanced MRI acquisition techniques has been more limited yet due to the specific and complex protocols which need a prospective study design, being 1H magnetic resonance spectroscopy a typical example.11 However, the potential of these techniques needs to be further taken use of. A range of processes shared with ALS impact ionic homeostasis including neuroinflammation and neurodegeneration by way of mitochondrial and sodium potassium pump (Na+/K+-ATPase) dysfunctions across the cell membrane, leading to intracellular sodium (Na+) and subsequent calcium overload in patients.12 These pathological processes could lead to homeostatic dysfunctions in motor regions and subsequent abnormal elevated sodium concentration in patients with ALS, while sodium dysbalance, in turn, could thus indicate early cellular dysfunction before degeneration of the cell.13 As a promising advanced MRI approach, total tissue sodium concentration (which is associated with the viability of cells) can be assessed by 23Na MRI.14,15 The technique has been applied to study brain tissue, given that the Na+ ion plays a crucial role in cell physiology as many conditions lead to changes in the average concentration of this element in cerebral tissue.16 Grapperon and colleagues used 23Na MRI to show that in patients with ALS, higher sodium concentration could be found in motor regions [bilateral precentral gyri, corticospinal tracts (CSTs), and corpus callosum].12

The 23Na concentration data are a volume-weighted average of 23Na assigned to the intra- and extracellular space, respectively. Thus, interstitial fluid, plasma, and cerebrospinal fluid (CSF) are attributed to the extracellular space; however, intracellular 23Na might be more indicative of pathological processes. In contrast to the 23Na concentration mapping, relaxation-based methods are a possibility to suppress 23Na with a longitudinal relaxation time such as in CSF,16 that way obtaining data with an increased weighting of intracellular space. Based on the differential sodium ion concentration between the intracellular and extracellular space, changes of the sodium ion concentration gradient point to pathological conditions, as investigated in neurodegenerative diseases like Huntington’s disease.17 Relaxation-weighted sodium MRI (23NaR) enables a further differentiation of the total sodium signal by suppressing sodium signal that originates from long T2* compartments such as in fluids.16 The aim of this study was to analyse the ALS-associated brain sodium homeostasis by applying 23NaR MRI to a group of participants with ALS in comparison to controls.

Methods

Subjects and patients
All participating patients and controls provided written informed consent for the study according to institutional guidelines. The study was approved by the Ethical Committee of the University of Ulm (reference #143/16).

The analysis included cross-sectional data from ALS patients (N=17) and controls (N=10; Table 1). All ALS patients underwent standardized clinical-neurological and routine laboratory examinations. The ALS patients (mean age 61.1 ± 11.4 years, m/f=9/8) presented with a sporadic form of clinically definite or probable ALS according to the revised El Escorial diagnostic criteria.18 Severity of physical symptoms, as measured with the revised ALS functional rating scale (ALS-FRS-R),19 was 40 ± 7 (range 24–46). Disease duration was 17 ± 13 months. None of the ALS patients had a history of any other neurological or psychiatric disorders or other medical conditions. None of the patients had any contraindications against MRI scanning. A normal database of age-matched healthy controls (mean age 60.3 ± 15.3 years, m/f=6/4, p=0.9 compared to ALS) was used for comparison. None had a history of neurological or psychiatric disease. The total acquisition period of this study was 1 year (11/2018 to 11/2019).

MRI acquisition
MRI scanning was performed on a 3.0 T Skyra (Siemens Medical, Erlangen, Germany) using a double-resonant (1H/23Na) quadrature birdcage coil (Rapid Biomedical GmbH, Rimpar, Germany). A double-echo, density-adapted 3D radial acquisition technique20 was applied with the following parameters: $TE_1 = 0.3$ ms, $TE_2 = 25.0$ ms, repetition time $TR = 100$ ms, readout duration $T_{RO} = 20$ ms,
nominal spatial resolution $4 \times 4 \times 4$ mm$^3$, flip angle: $90^\circ$, acquisition time: 13 min 20 s.

**MRI data analysis**

The pre- and postprocessing was performed by use of the analysis software Tensor Imaging and Fibre Tracking (TIFT).\textsuperscript{21}

**Stereotaxic normalization**

Stereotaxic normalization was done by a rigid-brain-transformation to AC–PC-line, followed by a non-affine normalization according to landmarks. Intensity was normalized according to regression of sodium signal intensities derived from six chambers filled with 2% agarose gels with different NaCl-concentrations (25, 50, 75, 100, 125, and 150 mmol/L);\textsuperscript{22} data processing is visualized in Figure 1.

**Relaxation weighting**

According to a previously published protocol,\textsuperscript{16} images with echo times $TE_1$ and $TE_2$ were subtracted using a weighted difference. The weighting factor $\exp[(TE_2-TE_1)/T_2^{\text{CSF}}]$ was chosen such that sodium ions exhibiting relaxation properties like in CSF were fully suppressed. For each voxel, the difference intensity $I_D$ (representing the sodium concentration) was calculated according to

$$ I_D(^{23}\text{Na}) = I(TE_1) - \exp \left[ \frac{TE_2 - TE_1}{T_2^{\text{CSF}}} \right] I(TE_2) \quad (1) $$

with $TE_1 = 0.3$ ms and $TE_2 = 25.0$ ms, and $T_2^{\text{CSF}} = 56$ ms, the weighting factor calculates as 1.554 (Figure 1).

The resulting difference maps were then smoothed with a Gaussian filter of FWHM 4 mm to obtain a good balance between sensitivity and specificity.

**ROI analyses**

Based on the staging concept, ROI analysis was performed by locating spherical ROIs at predefined positions in the stereotaxically normalized difference maps, i.e. upper CST, frontal lobes, and basal ganglia. The corresponding anatomical localizations were selected in a hypothesis-guided approach according to results of previous MRI studies\textsuperscript{9,23–25} where brain alterations have already been identified in accordance with the phosphorylated 43 kDa TAR DNA-binding protein (pTDP-43)-associated ALS propagation pattern.\textsuperscript{4,26} As a reference region, an ROI was placed in the callosal area V where no involvement in ALS-associated neurodegeneration could be anticipated. Methodologically, the size of the ROIs was varied between 7 and 15 mm in order to investigate the dependence of differences between ALS patients and controls on ROI size. ROI positions were also varied by 5 mm in each spatial direction, that way detecting the optimum position at maximum differences between ALS patients and controls.

For comparison, ROI analysis in the upper CST, basal ganglia, and, as a reference, callosal area V was performed in $^{23}$Na concentration maps.
(TE1 = 0.3 ms). For correlation analyses, Spearman correlation was calculated to assess potential associations of regional 23Na accumulation (23NaR MRI mapping as well as 23Na concentration mapping) with the clinical deficits (ALS-FRS-R) and disease duration, respectively.

**Results**

To analyse sodium concentration alterations that are localized in the CST, i.e. related to ALS stage 1, ROI locations in the upper CST were chosen. As additional ROI locations, we selected the frontal lobes and the basal ganglia, related to ALS stages 2 and 3, respectively; furthermore, an ROI was placed in the callosal area V as a reference region for comparison where no ALS-associated affectation could be anticipated. In order to validate the choice of the ROIs, the variation both of the size of the ROIs and of the ROI localizations are summarized in Supplementary Figure 1.

A significant increase of sodium concentration in ALS patients at the group level was observed in the upper CST (p < 0.0005) and in the frontal lobes (p < 0.01) when compared to controls, as demonstrated in Figure 2. A trend for sodium concentration increase was observed in the basal ganglia (p = 0.2). No significant differences were observed in the callosal area V (reference region, p = 0.9). For comparison, the ROI analysis in 23Na concentration maps (TE1 = 0.3 ms) revealed significantly increased 23Na accumulation in the upper CST (ALS patients: 44 mmol/L; controls: 41 mmol/L; p < 0.05) and in the frontal lobes.
(ALS patients: 43 mmol/L; controls: 39 mmol/L; \( p < 0.05 \)); a trend of increased \(^{23}\text{Na}\) concentration was observed in the basal ganglia (ALS patients: 40 mmol/L; controls: 37 mmol/L; \( p = 0.5 \)); no significant alterations were observed in the callosal area V (reference) (ALS patients: 43 mmol/L; controls: 44 mmol/L; \( p = 0.8 \); Supplementary Figure 2). Spearman correlation demonstrated no significant associations of the ROIs in the upper CST, frontal lobes, and basal ganglia with the ALS-FRS-R scores or with disease duration, respectively, neither for relaxation-weighted maps nor for concentration maps.

Discussion

\(^{23}\text{NaR}\) MRI as an advanced metabolic imaging technique of the brain was shown to be capable to provide deeper insights into the pathophysiological mechanisms of tissue degeneration in ALS by localizing changes of cerebral tissue sodium concentration in ALS. The regional patterns of sodium homeostasis which could be identified included first, motor areas (i.e. upper CST) as the most prominent finding and second, frontal areas. As such, this topography of abnormal sodium concentration mirrored elements of the neuropathologically defined cerebral pTDP-43 distribution patterns of ALS, spreading from the motor neocortex downwards and then to frontal and last, parietal and anteromedial temporal lobes.\(^4,26\) The involvement of primary motor cortices and CSTs in fact correspond to the core elements of the ALS pathoanatomy in the central nervous system, as has already been demonstrated in vivo by other MRI approaches like DTI.\(^{27}\)

\(^{23}\text{NaR}\) MRI as an advanced metabolic imaging technique has shown to be an improvement compared to \(^{23}\text{Na}\) concentration mapping; despite limited subject numbers, these results of the ROI analysis in \(^{23}\text{Na}\) concentration maps (\( TE_1 = 0.3 \text{ ms} \)) and of the ROI analysis in \(^{23}\text{NaR}\) maps.
are in accordance with previous results in sodium MRI. Spearman correlation demonstrated no association of the ROIs in any of the investigated structures with ALS-FRS-R or with disease duration; here, the assumption is that a data sample of 17 patients might be too low to perform this association analysis. The acquisition time of $^{23}\text{Na}\text{R MRI}$ of less than 15 minutes can be regarded as an acceptable burden even for ALS patients in an advanced stage of disease. The regions which showed a common pattern of abnormally elevated sodium concentration correspond to the stages 1 and 2 of the central nervous system (CNS) pathology in ALS; the fact that the upper CST constituted the key area of the highest significant alterations is in line with other current studies in which the upper CST was identified as the region of the highest normalized importance across the most relevant imaging variables in computational models for the analysis of MRI data in ALS. As such, findings in the current data may reflect the common pattern of CNS affection found across the investigated ALS patients despite their heterogeneity of disease burden.

Thus, these findings support the hypothesis that elevated brain tissue sodium concentration as a measure of loss of cell integrity could be a potential marker of neurodegeneration processes; several pathophysiological processes involved in ALS, including mitochondrial dysfunction (as reported in ALS), ionic disturbances, neuronal hyperexcitability, and neuroinflammation, could contribute to the altered sodium concentration observed in our and previous studies. As such, the intraneuronal sodium overload may reflect both energy failure and axonal hyperexcitability as features of ALS.

The application of relaxation-weighted $^{23}\text{Na}\text{MRI}$ offers the possibility to assess the fluid-suppressed sodium signal and to achieve a weighting towards the intracellular space. However, data quality control and analysis have to be thoroughly performed, given that the weighted subtraction image is more prone to susceptibility artefacts. The finding of regional sodium signal increase in $^{23}\text{Na}\text{R MRI}$ (in contrast to signal reduction in $^{23}\text{Na}\text{MRI}$, as it would be expected in association with local atrophy) might be due to the structure alterations and dysfunction of mitochondria which is regarded as a player in the pathogenesis of ALS, partially overlapping with other neurodegenerative diseases. Although, the ROI-based analysis was able to identify sodium increase in specific regions, the signal-to-noise ratio of the data sample of this study did not allow to detect sodium alteration along specific ALS-related tracts.

Conclusion
In summary, this study provides evidence that $^{23}\text{Na}\text{MRI}$ depicts abnormal sodium concentration specifically in brain regions known to be particularly vulnerable in ALS and which correspond to the stages 1 and 2 of the pTDP-43 pathology of ALS. This mapping of tissue sodium concentration alterations could be a promising imaging biomarker to non-invasively analyse the regional cellular and metabolic integrity associated with neurodegeneration and might guide in monitoring the effects of therapeutic options which address e.g. mitochondrial dysfunction.
Declarations

Ethics approval and consent to participate
All participating patients and controls provided written informed consent for the study according to institutional guidelines. The study was approved by the Ethical Committee of the University of Ulm (reference #143/16).

Consent for publication
All authors have agreed on publication.

Author contributions
Hans-Peter Müller: Conceptualization; Formal analysis; Methodology; Writing – original draft.
Armin M. Nagel: Conceptualization; Investigation; Methodology; Writing – review & editing.
Franziska Keidel: Methodology; Writing – review & editing.
Arthur Wunderlich: Methodology; Writing – review & editing.
Annemarie Hübers: Methodology; Writing – review & editing.
Lena V. Gast: Methodology; Writing – review & editing.
Albert C. Ludolph: Investigation; Writing – review & editing.
Meinrad Beer: Conceptualization; Investigation; Writing – review & editing.
Jan Kassubek: Conceptualization; Investigation; Supervision; Writing – original draft.

ORCID iDs
Armin M. Nagel https://orcid.org/0000-0003-0948-1421
Annemarie Hübers https://orcid.org/0000-0002-3088-0366
Jan Kassubek https://orcid.org/0000-0002-7106-9270

Acknowledgements
The authors would like to thank the Ulm University Center for Translational Imaging MoMAN for its support.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. An associate editor of Therapeutic Advances in Chronic Disease is an author of this paper; therefore, the peer-review process was managed by alternative members of the Board, and the Editor had no involvement in the decision-making process.

Availability of data and materials
Data are available upon reasonable request. Reasonable data sharing requests are made in writing through Jan Kassubek (jan.kassubek@uni-ulm.de) and require a formal data sharing agreement. Data sharing agreements must include details on how the data will be stored, who will have access to the data and intended use of the data, and agreements as to the allocation of intellectual property.

Supplemental material
Supplemental material for this article is available online.

References
1. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet 2017; 390: 2084–2098.
2. Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 2022; 21: 480–493.
3. Grossman M. Amyotrophic lateral sclerosis – a multisystem neurodegenerative disorder. Nat Rev Neurol 2019; 15: 5–6.
4. Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis – a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708–714.
5. Kassubek J and Müller HP. Advanced neuroimaging approaches in amyotrophic lateral sclerosis: refining the clinical diagnosis. Expert Rev Neurother 2020; 20: 237–249.
6. Chiò A, Pagani M, Agosta F, et al. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol 2014; 13: 1228–1240.
7. Kassubek J and Pagani M. Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol 2019; 32: 740–746.
8. Kocar TD, Müller HP, Ludolph AC, et al. Feature selection from magnetic resonance imaging data in ALS: a systematic review. Ther Adv Chronic Dis 2021; 12: 20406223211051002.
9. Müller HP, Turner MR, Grosskreutz J, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 570–579.

10. Filippi M, Agosta F, Grosskreutz J, et al. Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2015; 14: 786–788.

11. Kalra S. Magnetic resonance spectroscopy in ALS. Front Neurol 2019; 10: 482.

12. Grapperon AM, Ridley B, Verschueren A, et al. Quantitative brain sodium MRI depicts corticospinal impairment in amyotrophic lateral sclerosis. Radiology 2019; 292: 422–428.

13. Boada FE, LaVerde G, Jungreis C, et al. Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. Curr Top Dev Biol 2005; 70: 77–101.

14. Madelin G, Lee JS, Regatte RR, et al. Sodium MRI: methods and applications. Prog Nucl Magn Reson Spectrosc 2014; 79: 14–47.

15. Huhn K, Engelhorn T, Linker RA, et al. Potential of sodium MRI as a biomarker for neurodegeneration and neuroinflammation in multiple sclerosis. Front Neurol 2019; 10: 84.

16. Nagel AM, Bock M, Hartmann C, et al. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol 2011; 46: 539–547.

17. Reetz K, Romanzetti S, Dogan I, et al. Increased brain tissue sodium concentration in Huntington’s Disease – a sodium imaging study at 4 T. NeuroImage 2012; 63: 517–524.

18. Brooks BR, Müller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–299.

19. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21.

20. Nagel AM, Laun FB, Weber MA, et al. Sodium MRI using a density-adapted 3D radial acquisition technique. Magn Reson Med 2009; 62: 1565–1573.

21. Müller HP, Unrath A, Ludolph AC, et al. Preservation of diffusion tensor properties during spatial normalization by use of tensor imaging and fibre tracking on a normal brain database. Phys Med Biol 2007; 52: N99–N109.

22. Mirkes CC, Hoffmann J, Shajan G, et al. High-resolution quantitative sodium imaging at 9.4 Tesla. Magn Reson Med 2015; 73: 342–351.

23. Kassubek J, Müller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 2014; 137: 1733–1740.

24. Kalra S, Müller HP, Ishaque A, et al. A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS. Neurology 2020; 95: e943–e952.

25. Bede P, Elamin M, Byrne S, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology 2013; 81: 2107–2115.

26. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20–38.

27. Kassubek J, Müller HP, Del Tredici K, et al. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry 2018; 89: 374–381.

28. Bede P, Murad A and Hardiman O. Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features. J Neurol 2022; 269: 2440–2452.

29. Turner MR, Bowser R, Bruijn L, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14(Suppl. 1): 19–32.

30. Vucic S and Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006; 117: 1458–1466.

31. Jankovic M, Novakovic I, Gamil Anwar Dawod P, et al. Current concepts on genetic aspects of mitochondrial dysfunction in amyotrophic lateral sclerosis. Int J Mol Sci 2021; 22: 9832.

32. Kline RP, Wu EX, Petrylak DP, et al. Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. J Nucl Med 2019; 60: 2146–2156.

33. Konstandin S and Nagel AM. Measurement techniques for magnetic resonance imaging of fast relaxing nuclei. MAGMA 2014; 27: 5–19.

34. Ridley B, Nagel AM, Bydder M, et al. Distribution of brain sodium long and short relaxation times and concentrations: a multi-echo ultra-high field 23Na MRI study. Sci Rep 2018; 8: 4357.

35. Gilles A, Nagel AM and Madelin G. Multipulse sodium magnetic resonance imaging for multicompartiment quantification: proof-of-concept. Sci Rep 2017; 7: 17435.